TenNor Therapeutics, a clinical-stage pharmaceutical company based in China, has announced the successful completion of its Series E financing round, raising RMB 300 million (USD 42.16 million). The financing was co-led by Zhongshan Venture Capital and the AMR Action Fund. The funds raised will be directed towards the late-stage clinical trials and commercialization efforts for the company’s core drug pipelines, specifically TNP-2198 (rifasutenizol) for treating Helicobacter pylori infection and TNP-2092 (rifaquizinone) for infections caused by implanted medical devices.
Specializing in the discovery and development of “first-in-class” or “best-in-class” new drug products for bacterial infection and metabolic diseases, TenNor Therapeutics has made significant strides in its pipeline. TNP-2198 has completed Phase III clinical studies and has been granted Qualified Infectious Disease Product (QIDP) and Fast Track designations by the U.S. Food and Drug Administration (FDA). TNP-2092, a novel triple-targeting drug candidate, has concluded Phase II studies and is expected to tackle the dual challenges of antimicrobial resistance and persistence in medical device infections. Other drug candidates within TenNor’s pipeline have also advanced into late stages of development.- Flcube.com
